## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors report that BLACE, a non-coding RNA specifically expressed in B-cell acute lymphoblastic leukemia (B-ALL), shows elevated expression in both pediatric and adult B-ALL patients. They identify promoter elements (CAAT box, TATA box, G-rich sequences) and a TAL1 transcription factor binding site overlapping a G-rich sequence at -1291 bp. They report a correlation between TAL1 and BLACE expression, and docking studies showing a binding score of -208.68 kcal/mol with 21 nucleotide-residue interactions. They conclude that BLACE could serve as a new therapeutic target.
- **Visible evidence base** Abstract text only; no sample sizes, statistical details, experimental methods, or docking validation metrics are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, patient cohort details, statistical analysis, experimental protocols, docking methodology and validation, and any supplementary data

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting finding regarding a B-ALL-specific non-coding RNA and its possible regulation by TAL1. However, the evidence base is too limited to evaluate the validity of the central claims. Key quantitative data, such as sample sizes, expression fold changes, statistical significance, and docking validation, are absent. The conclusion that BLACE is a therapeutic target is not supported by the provided evidence, which is largely descriptive and in silico.
- **Who would be interested in the results, and why** Researchers in hematological malignancies, particularly those studying B-ALL biomarkers and non-coding RNA regulation, would find the identification of a B-ALL-specific transcript and its potential TAL1-mediated regulation of interest. The promoter analysis and docking results may also appeal to computational biologists working on transcription factor binding and RNA-protein interactions.
- **Major strengths** The focus on a B-ALL-specific transcript addresses a clinically relevant need for better diagnostic and therapeutic targets. The combination of transcriptional analysis with promoter characterization and docking is a multi-pronged approach that, if rigorously executed, could provide a useful framework for studying non-coding RNAs in leukemia.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4
- **Assessment against Nature-style criteria**  
  - Originality: Moderate. The concept of a B-ALL-specific non-coding RNA is not entirely novel, but the specific focus on BLACE and its TAL1 interaction may offer a new angle.  
  - Scientific importance: Potentially relevant to B-ALL diagnostics and therapy, but the clinical significance is not established from the abstract.  
  - Interdisciplinary readership: The work spans molecular biology, bioinformatics, and structural biology, which could attract a broad audience if the evidence is robust.  
  - Technical soundness: Cannot be assessed from the abstract alone; critical details on sample size, statistics, and docking validation are missing.  
  - Readability for nonspecialists: The abstract is generally clear, but terms like "G-quadruplexes" and "docking interface" may require background knowledge.  
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a promising direction, but the lack of quantitative and methodological detail prevents a supportive recommendation. A revised manuscript with full data would be needed for a fair assessment.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence sufficiency  
- **Claim pointer** "Expression of BLACE was high in both pediatric and adult ALL patients."  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract does not report the number of patients, control groups, expression quantification method, or statistical significance. Without these, the claim of "high" expression is unverifiable.  
- **Why it matters** The central diagnostic claim rests on demonstrating a significant difference in BLACE expression between B-ALL patients and appropriate controls. Without sample sizes and statistics, the claim is anecdotal.  
- **Resolution test** Provide cohort size, control types, expression values (e.g., fold change, normalized counts), and p-values or confidence intervals.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical validity  
- **Claim pointer** "Expression of TAL1 gene was measured and found to correlate with the BLACE expression."  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The correlation coefficient, sample size, and statistical method are not reported. A correlation could be spurious or driven by outliers.  
- **Why it matters** The proposed regulatory relationship between TAL1 and BLACE is a key mechanistic claim. Without robust correlation statistics, the link is not established.  
- **Resolution test** Report the correlation coefficient (e.g., Pearson or Spearman), p-value, and sample size, and show a scatter plot in the full manuscript.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical validity  
- **Claim pointer** "The docking studies performed between BLACE-TAL1 protein showed a binding score of -208.68 kcal/mol and identified 21 BLACE nucleotide - TAL1 residues interacting at the docking interface."  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The docking score is presented without context. No software, scoring function, or validation (e.g., experimental binding data, molecular dynamics, or comparison to known complexes) is provided. A single score is insufficient to support a functional interaction.  
- **Why it matters** The therapeutic target claim depends on a specific and stable interaction between BLACE and TAL1. Without validation, the docking result is speculative.  
- **Resolution test** Provide docking methodology, include a control or known interaction for comparison, and ideally support with experimental binding assays or molecular dynamics simulations.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Claim scope  
- **Claim pointer** "BLACE gene specifically expressed in B-cell ALL could serve as a new therapeutic target."  
- **Evidence pointer** Abstract, location not provided  
- **Concern** The abstract provides no functional data (e.g., knockdown or overexpression studies) to show that modulating BLACE affects leukemia cell viability or proliferation. The term "therapeutic target" implies a functional role that is not demonstrated.  
- **Why it matters** A therapeutic target must be shown to be functionally relevant, not merely differentially expressed. The current evidence is descriptive and in silico.  
- **Resolution test** Include functional assays showing that BLACE knockdown or overexpression alters B-ALL cell behavior, or clearly reframe the claim as a hypothesis.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Promoter analysis description  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract states the presence of CAAT and TATA boxes and G-rich sequences but does not specify the promoter region analyzed or the method used.  
- **Required correction** Specify the promoter coordinates and the prediction tools or experimental methods used.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Terminology  
- **Affected element** "BLACE-TAL1 protein"  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The phrase "BLACE-TAL1 protein" is ambiguous because BLACE is described as a non-coding RNA, not a protein.  
- **Required correction** Rephrase to "docking between BLACE RNA and TAL1 protein" for clarity.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Completeness  
- **Affected element** Study limitations  
- **Evidence pointer** Abstract, location not provided  
- **Issue** The abstract mentions "further investigations are required" but does not specify what limitations drive this need.  
- **Required correction** Briefly state the main limitations, such as small sample size or lack of functional validation, to contextualize the need for future work.

## Risk / unsupported claims
- The claim that BLACE expression is "high" in B-ALL patients is unsupported due to missing quantitative data and statistics.
- The correlation between TAL1 and BLACE expression is unsupported without correlation coefficients and significance testing.
- The docking result is presented as evidence of interaction but lacks methodological detail and validation, making it unverifiable.
- The conclusion that BLACE is a therapeutic target is unsupported by functional evidence and exceeds the scope of the descriptive and in silico data presented.